In sur­prise flop, Re­gen­eron, Sanofi re­port Dupix­ent PhI­II fail­ure, trig­ger­ing pre­ma­ture tri­al stop

Dupix­ent, the seem­ing­ly in­fal­li­ble an­ti-in­flam­ma­to­ry drug joint­ly de­vel­oped by Re­gen­eron and Sanofi, has flopped in a Phase III study.

Giv­en to pa­tients with chron­ic spon­ta­neous ur­ticaria — a con­di­tion char­ac­ter­ized by the con­stant pres­ence of hives — Dupix­ent failed to reach sta­tis­ti­cal sig­nif­i­cance on the pri­ma­ry end­points of re­duc­ing itch and hives at an in­ter­im analy­sis.

Re­gen­eron and Sanofi said the tri­al will be stopped due to fu­til­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER